Showing 5111-5120 of 21466 results for "".
- Revision Skincare Names Marco Ficarelli Chief Global Growth Officerhttps://reachmd.com/news/revision-skincare-names-marco-ficarelli-chief-global-growth-officer/2487628/Revision Skincare has appointed Marco Ficarelli as chief global growth officer, effective June 22, 2026, as the physician-dispensed skincare company continues to expand its international presence and digital business. Ficarelli joins the company with experience in global commercial leaders
- Generative AI Decision Support in Kenyan Primary Care Trialhttps://reachmd.com/news/generative-ai-decision-support-in-kenyan-primary-care-trial/2487604/Key Takeaways The intervention arm showed no statistically significant difference in expert-adjudicated treatment failure within 14 days. Clinicians using the tool produced better diagnostic documentation and treatment plans in reviewed encounters.
- MAF-5 Score and Liver-Related Event Risk in a Screening Cohorthttps://reachmd.com/news/maf-5-score-and-liver-related-event-risk-in-a-screening-cohort/2487605/Key Takeaways Liver-related event risk rose across low-, intermediate-, and high-risk MAF-5 categories. Adding age improved discrimination and further separated risk within the same MAF-5 strata. Comparisons with FIB-4, APRI, and NFS plus comb
- Veligrotug in Active Thyroid Eye Disease: THRIVE Phase 3 Trialhttps://reachmd.com/news/veligrotug-in-active-thyroid-eye-disease-thrive-phase-3-trial/2487607/Key Takeaways Week 15 primary and secondary outcomes favored veligrotug over placebo, with reported comparisons meeting P < 0.001. Improvement was observed by week 3, and 70% of initial responders maintained proptosis response at week 52. T
- Alzheimer Trial Design And Atypical Variantshttps://reachmd.com/news/alzheimer-trial-design-and-atypical-variants/2487611/As disease-modifying therapies for Alzheimer's disease (AD) become increasingly available, researchers are calling attention to a group of patients who have historically been overlooked in clinical trials: those with atypical variants of the disease.
- Lonvoguran Ziclumeran Lowers Hereditary Angioedema Attackshttps://reachmd.com/news/lonvoguran-ziclumeran-lowers-hereditary-angioedema-attacks/2487603/Key Takeaways A single infusion of lonvoguran ziclumeran was associated with a substantially lower monthly hereditary angioedema attack rate than placebo. The phase 3, double-blind trial randomized 80 patients in a 2:1 ratio to one 50-mg intravenous do
- Self-Directed CBT-CP Outperformed Clinician-Delivered CBT in VHA Trialhttps://reachmd.com/news/self-directed-cbt-cp-outperformed-clinician-delivered-cbt-in-vha-trial/2487610/Key Takeaways Self-directed CBT-CP was associated with lower pain-interference scores at the primary 4-month assessment, and the between-group difference persisted at 6 and 12 months. At 4 months, all other prespecified patient-reported outcomes favore
- Longitudinal Mammographic Deep Learning Risk Scores Track Future Cancerhttps://reachmd.com/news/longitudinal-mammographic-deep-learning-risk-scores-track-future-cancer/2487609/Key Takeaways Scores increased over time before breast cancer diagnosis and remained comparatively stable in women who stayed cancer free. The modeled yearly increase was steeper in the cancer group, and the same overall pattern appeared across age and
- Study Shows Racial Differences in Pseudofolliculitis Barbae Complications, Treatment Timinghttps://reachmd.com/news/racial-differences-in-pfb-complications-treatment-timing-highlight-care-gaps/2487632/A multicenter retrospective cohort study published as a Letter to the Editor in the Journal of Drugs in Dermatology found that Black patients with pseudofolliculitis barbae (PFB) experienced significantly higher rates of post-inflammatory hyperpigmentation (PIH) and hypertrophic scarring
- Standing Orders Boost Vaccine Uptake In Systematic Reviewhttps://reachmd.com/news/standing-orders-boost-vaccine-uptake-in-systematic-review/2487602/Key Takeaways Across clinical settings, standing orders were generally associated with higher vaccine uptake in studies that evaluated them. Seasonal influenza and pneumococcal vaccination were the most represented outcomes, and their results moved in